在患有早期心力衰竭的患者中,左心室喷射小部分改善的预测因素与减少喷射小部分
Li-Ting Ho1,2,3, Jyh-Ming Jimmy Juang1,2, Ying-Hsien Chen1,2
1Division of Cardiology, Department of Internal Medicine.
Acta Cardiologica Sinica
|November 29, 2023
概括
贝塔阻塞剂的使用预测心力衰竭患者的喷射分数有所改善. 改善喷射分数 (HFimpEF) 的患者的死亡率低于持久减少喷射分数 (HFrEF) 的患者.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭研究研究
- 临床结果 临床结果
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭是一个重大的临床挑战.
- 左心室喷射分数 (LVEF) 恢复是HFrEF管理的一个关键目标.
- 了解LVEF恢复和不同HF表型的结果的预测因素至关重要.
研究的目的:
- 在HFrEF患者中确定LVEF恢复的预测因素.
- 为了比较HFrEF患者和那些通过改善射出分数 (HFimpEF) 达到心力衰竭的患者之间的死亡率.
主要方法:
- 对259名患者在急性后护理计划 (2018-2021) 中进行的回顾性分析.
- 用于将患者分类为HFimpEF,持续的HFrEF或轻微减少的喷射分数的心声图.
- 多变量后勤回归和生存分析以确定预测因素并比较死亡率.
主要成果:
- 158名患者 (61%) 实现了HFimpEF;87名 (33.6%) 患有持续的HFrEF.
- 贝塔阻断剂处方是HFimpEF的唯一独立预测因子 (OR 2.11).
- 缺血性心肌病诊断和QRS持续时间≥110毫秒是HFimpEF的负预测因素.
- 与持久性HFrEF患者相比,HFimpEF患者的死亡率 (HR 0.2) 显著降低.
结论:
- 贝塔抑制剂治疗与HFrEF患者的LVEF改善有关.
- 缺血性心肌病和延长的QRS持续时间与较差的LVEF恢复有关.
- 获得HFimpEF地位显著降低了心力衰竭患者的死亡风险.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:22Heart Failure Drugs: β-Blockers
342
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
01:22Heart Failure Drugs: Diuretics
396
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
396